Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

(2021) Jennifer M. Dan et al.   SCIENCE

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

(2021) Anja Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

(2021) Noa Dagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases

(2021) Robert Spiera et al.   ANNALS OF THE RHEUMATIC DISEASES

LB0003 IMMUNOGENICITY AND SAFETY OF THE BNT162b2 mRNA COVID-19 VACCINE IN ADULT PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND GENERAL POPULATION: A MULTICENTER STUDY

(2021) V. Furer et al.   ANNALS OF THE RHEUMATIC DISEASES

Seroconversion rates following COVID-19 vaccination among patients with cancer

(2021) Astha Thakkar et al.   CANCER CELL

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

(2021) Erin M. Bange et al.   NATURE MEDICINE

Brief Report: Humoral and cellular immune responses to SARS‐CoV‐2 infection and vaccination in B cell depleted autoimmune patients

(2021) David Simon et al.   Arthritis & Rheumatology

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

(2021) Kazimieras Maneikis et al.   Lancet Haematology

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

(2020) Wenhua Liang et al.   LANCET ONCOLOGY

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases

(2020) D. Baker et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Preliminary evaluation of Roche Cobas Elecsys Anti-SARS-CoV-2 chemiluminescence immunoassay

(2020) Giuseppe Lippi et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Validation of a commercially available SARS-CoV-2 serological immunoassay

(2020) B. Meyer et al.   CLINICAL MICROBIOLOGY AND INFECTION

The Influence of Different Disease States on Rituximab Pharmacokinetics

(2020) Xiaoxing Wang et al.   CURRENT DRUG METABOLISM

Accuracy of serological testing for SARS‐CoV‐2 antibodies: first results of a large mixed‐method evaluation study

(2020) D. Brigger et al.   ALLERGY

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

(2020) Takuya Sekine et al.   CELL

Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak

(2020) Jose Portolés et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

A8.10 The effect of rituximab treatment on B and T cell subsets in lymphoid tissues of patients with rheumatoid arthritis

(2015) TH Ramwadhdoebe et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab

(2014) Ulrich Storz   mAbs